Infections due to the herpesvirus group in immunocompromised patients

Current Opinion in Infectious Diseases

Volumn 11, Issue 4, 1998, Pages 425-430

  Ward, Katherine Nora ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR;

CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; REVIEW; SIDE EFFECT; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; VIRUS LATENCY;

EID: 0031826011     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199808000-00005     Document Type: Review

References (65)

1. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin • Microbiol Rev 1997; 10:1-86. This is a comprehensive and well written review.
2. Ward KN. Viral complications after bone marrow transplantation. PHLS Microbiology Digest 1996; 13:16-19.
3. Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19:287-298.
4. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden R. Cytomegalovirus pp65 antigenaemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomised double-blind study. Blood 1996; 88:4063-4071.
5. Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, Paya CV. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplant 1996; 61:1279-1289.
6. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261:3561-3566.
7. Ettinger NA, Bailey TC, Trulock EP, Storch GA, Anderson D, Raab S, et al. and the Washington University Lung Transplant Group. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Am Rev Respir Dis 1993; 147:1017-1023.
8. Furukawa H, Manex R, Kusne S, Abu-Elmagd K, Green M, Reyes G, et al. Cytomegalovirus disease in intestinal transplantation. Transplant Proc 1995; 27:1357-1358.
9. Reusser P. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect 1996; 33:235-248.
10. Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF, Sturzenegger S, Kaplan M, et al. Isolation of a new virus, (HBLV), in patients with lymphoproliferative disorders. Science 1986; 234:596-601.
11. Singh N, Carrigan DR. Human herpesvirus-6 in transplantation: an emerging pathogen. Ann Intern Med 1996; 124:1065-1071.
12. + T cells. Proc Natl Acad Sci USA 1990; 87:748-752.
13. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-1869.
14. Schulz TF. KSHV/HHV-8: the cause of Kaposi's sarcoma or another ubiquitous human herpesvirus. PHLS Microbiology Digest 1996; 13:29-32.
15. Rasmussen L, Hong C, Zipeto D, Morris S, Sherman D, Chou S, et al. Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipients. J Infect Dis 1997; 175:179-184.
16. Torokstorb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T. • Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood 1997; 90:2097-2102. A retrospective study analysed CMV infection and myelosuppression in relation to viral glycoprotein B (gB). The endpoint of interest was death from bacterial and fungal complications of neutropenia, which were found to be significantly associated with the relatively rare gB genotypes 3 and 4.
17. Sinclair J, Sissons JGP. Human cytomegalovirus: pathogenesis and models of latency. Semin Viral 1994; 5:249-258.
18. Sindre H, Tjonnifjord GE, Rollag H, Rannebergnilsen T, Veiby OP, Beck S, ef al. Human cytomegalovirus suppression of and latency in early hematopoietic progenitor cells. Blood 1996; 88:4526-4533.
19. +) bone marrow progenitors. J Gen Virol 1996; 77:3099-3102.
20. Söderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human •• cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91:119-126. This paper shows conclusively that cells of the myeloid lineage harbour CMV and that permissiveness of such cells for CMV replication is critically dependent on the differentiation state of the cell. CMV is demonstrated to reactivate in macrophages on allogeneic stimulation in vitro. This experimental system can be used to identify mechanisms involved in the maintenance of CMV latency and to explore the cellular activation pathways that mediate CMV reactivation. Additionally, this cell culture system will provide a way to examine mechanisms of CMV immunological surveillance as well as therapeutic approaches to prevent viral reactivation.
21. Falagas ME, Syndman DR, Griffith J, Ruthazer R, Werner BG, Rohrer R, et al. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med 1997: 126:275-279.
22. Bueno J, Green M, Kocoshis S, Furukawa H, Abu-Elmagd K, Yunis E, et al. Cytomegalovirus infection after intestinal transplantation in children. Clin Infect Dis 1997; 25:1078-1083.
23. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied NJ, Camara R, ef al, for the European Acyclovir for CMV Prophylaxis Study Group. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. Bone Marrow Transplant 1997; 19:129-133.
24. Prentice HG, Kho P. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. Bone Marrow Transplant 1997; 19:135-142.
25. King SM, Superina R, Andrews W, Winston DJ, Dunn S, Busuttil RW, et al. Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. Clin Infect Dis 1997; 25:1173-1179.
26. Gane E, Saliba F, Valdecasas GJC, O'Grady J, Pescovte MD, Lyman S, Robinson CA. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350:1729-1733.
27. Winston D, Wirin D, Shaked A, Busuttil R. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant patients. Lancet 1995; 346:69-74.
28. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies. Bone Marrow Transplant 1996; 18:347-353.
29. Takenaka K, Gondo H, Tanimoto K, Nagafuji K, Fujisaki T, Mizuno S, et al, and the Fukuoka Bone Marrow Transplantation Group. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. Bone Marrow Transplant 1997; 19:241-248.
30. 9/I.
31. Ippolrti C, Morgan A, Warkentin D, van Besien K, Mehra R, Khouri I, et al. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant 1997; 20:491-495.
32. Bacigalupo A, Bregante S, Tedone E, Isaza A, van Lint MT, Trespi G, et al. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 1996; 62:376-380.
33. Hebart H, Muller C. Löffler J. Jahn G, Einsele H. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant 1996; 17:861-868.
34. Boeckh M, Gallezhawkins GM, Myerson D. Zaia JA. Bowden RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation - comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997; 64:108-113.
35. Grundy JE, Ehrnst A, Einsele H, Emery VC, Hebart H, Prentice HG, Ljungman P. A three centre European quality control study of PCR detection of cytomegalovirus DNA in blood. J Clin Microbiol 1996; 34:1166-1170.
36. Limaye AP, Bowden RA, Myerson D. Boeckh M. Cytomegalovirus disease occurring before engraftment in marrow transplant recipients. Clin Infect Dis 1997; 24:830-835.
37. Imbert-Marcille BM, Cantarovich D, Ferre-Aubineau V, Richet B, Soulillou JP, Billaudel S. Usefulness of DNA viral load quantification for cytomegalovirus disease monitoring in renal and pancreas/renal transplant recipients. Transplantation 1997; 63:1476-1481.
38. Zaia JA, Gallezhawkins GM, Tegtmeier BR, Terveer A, Li XL, Niland JC, Forman SJ. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997; 176:782-785.
39. Cope AV, Sabin C. Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176:1484-1490.
40. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD, Emery VC. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/ recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21:597-605.
41. Schäfer P, Tenschert W, Cremaschi L, Gutensohn K, Laufs R. Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR. J Clin Microbiol 1998; 36:1008-1014.
42. Salzberger B, Myerson D, Boeckh M. Circulating cytomegalovirus (CMV)-infected endothelial cells in marrow transplant patients with CMV disease and CMV infection. J Infect Dis 1997; 176:778-781.
43. Boeckh M, Hoy C, Torok-Storb B. Occult cytomegalovirus infection of marrow stroma. Clin Infect Dis 1998; 26:209-210.
44. Reusser P, Cordonnier C, Einsele H, Engelhard D, Link H, Locasciulli A, Ljungman P. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 1996; 17:813-817.
45. Rosen HR, Benner KG, Flora KD, Rabkin JM, Orloff SL. Olyaei A. Chou SW. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997; 63:476-478.
46. Alain S, Honderlick P, Grenet D, Stern M, Vadam C, Sansonlepors MJ. Mazeron MC. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient Transplantation 1997; 63:1533-1536.
47. Erice A, Gilroda C, Perez JL, Balfour HH, Sannerud KJ, Hanson MN, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175:1087-1092.
48. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. • High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176:69-77. A study showing that low-level ganciclovir-resistant isolates are associated with short periods of ganciclovir treatment and remain sensitive to cidofovir. whereas high-level ganciclovir-resistant isolates are associated with extended ganciclovir therapy and are resistant to cidofovir.
49. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al. • HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276:1719-1724. The first successful human test of a gene therapy designed to halt graft-versus-host disease.
50. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, Arvin AM. • Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunised with inactivated varicella vaccine. J Infect Dis 1997; 176:578-585. This paper provides the first evidence that specific immunization can reduce the morbidity caused by herpesvirus reactivation in BMT patients.
51. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE. Correlative morphological and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85:552-565.
52. Mañez R, Breinig MC, Linden P, Wilson J. Torre-Cisneros J, Kusne S, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176:1462-1467.
53. Orazi A, Hromas RA, Neiman RS, Greiner TC, Lee CH, Rubin L, et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997; 107:419-429.
54. Dockrell DH, Prada J, Jones MF, Patel R, Badley AD. Harmsen WS. el at. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997: 176:1135-1140.
55. Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients - documentation of pathogenicity. Transplantation 1997; 64:674-678.
56. Lautenschlager I. Hockerstedt K, Linnavuori K, Taskinen E. Human herpesvirus-6 infection after liver transplantation. Clin Infect Dis 1998; 26:702-707.
57. Drobyski WR, Knox KK, Majewski D, Carrigan DR. Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in a bone marrow transplant recipient. N Engl J Med 1994; 330:1357-1360.
58. Mookerjee BP, Vogelsang G, Human herpesvirus-6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir. Bone Marrow Transplant 1997; 20:905-906.
59. Bosi A, Zazzi M, Amantini A, Cellerini M. Vannucchi AM, De Milito A, et al Herpesvirus-6 fatal encephalitis after unrelated bone marrow transplantation Bone Marrow Transplant 1998; 22:285-288.
60. Chan PKS, Peiris JSM, Yuen KY. Liang RHS, Lau YL. Chen FE. et at. Human herpesvirus-6 and human herpesvirus-7 infections in bone marrow transplant recipients. J Med Virol 1997; 53:295-305.
61. Osman HK, Peiris JS. Taylor CE, Warwicker P. Jarrett RF, Madeley CR. 'Cytomegalovirus disease' in renal allograft recipients: is human herpesvirus-7 a cofactor for disease progression? J Med Virol 1996; 48:295-301.
62. Di Alberti L, Platelli A, Artese L, Favia G, Patel S, Saunders N, et al. Human herpesvirus-8 variants in sarcoid tissues. Lancet 1997; 350:1655-1661.
63. Rettig MB, Ma HJ, Vescio RA, Põld M, Schiller G, Belson D, et al. Kaposi's •• sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997; 276:1851-1854. HHV-8 was found in the bone marrow dendritic cells of multiple myeloma patients but not in malignant plasma cells or bone marrow dendritic cells from normal individuals or patients with other malignancies. Viral IL-6, the human homologue of which is a growth factor for myeloma, was found to be transcribed in the myeloma bone marrow dendritic cells. HHV-8 may be required for the development and perpetuation of myeloma cells.
64. Ganem D. KSHV and Kaposi's sarcoma: the end of the beginning? Cell 1997; 91:157-160. This minireview summarizes the evidence that HHV-8 (or Kaposi's sarcoma-associated herpesvirus) plays a critical role in the development of Kaposi's sarcoma, and considers some of the molecular mechanisms that might underly this association.
65. Michaels MG, Alcendor DJ, St George K, Rinaldo CR, Ehrlich GD, Becich MJ, Hayward GS. Distinguishing baboon cytomegalovirus from human cytomegalovirus; importance for xenotransplantation. J Infect Dis 1977; 176:1476-1483.